- Home
- NCV vs ABSI Comparison
NCV vs ABSI Comparison
Compare NCV & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCV | ABSI |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.6M | 997.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NCV | ABSI |
|---|---|---|
| Price | $15.00 | $10.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $14.40 |
| AVG Volume (30 Days) | 77.1K | ★ 3.3M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 12.48% | N/A |
| EPS Growth | N/A | ★ 10.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | N/A | $39.03 |
| Revenue Next Year | N/A | $314.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.46 | $2.24 |
| 52 Week High | $17.65 | $12.06 |
Technical Indicators
Market Signals| Indicator | NCV | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 28.34 | 62.14 |
| Support Level | $15.00 | $8.17 |
| Resistance Level | $15.67 | $11.26 |
| Average True Range (ATR) | 0.28 | 0.71 |
| MACD | -0.06 | 0.16 |
| Stochastic Oscillator | 13.97 | 87.30 |
Price Performance
Historical ComparisonAbout NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.